90 related articles for article (PubMed ID: 9499190)
21. Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow.
Heiss MM; Simon EH; Beyer BC; Gruetzner KU; Tarabichi A; Babic R; Schildberg FW; Allgayer H
J Clin Oncol; 2002 Apr; 20(8):2005-16. PubMed ID: 11956259
[TBL] [Abstract][Full Text] [Related]
22. [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
Zhao EM; Han DM; Yu ZK; Fan EZ; Li Y
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb; 38(1):39-42. PubMed ID: 12778766
[TBL] [Abstract][Full Text] [Related]
23. Prognostic impact of stromal cell-derived urokinase-type plasminogen activator in gastric carcinoma.
Okusa Y; Ichikura T; Mochizuki H
Cancer; 1999 Mar; 85(5):1033-8. PubMed ID: 10091785
[TBL] [Abstract][Full Text] [Related]
24. MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer.
Mrena J; Wiksten JP; Nordling S; Kokkola A; Ristimäki A; Haglund C
J Clin Pathol; 2006 Jun; 59(6):618-23. PubMed ID: 16731602
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer.
Harvey SR; Hurd TC; Markus G; Martinick MI; Penetrante RM; Tan D; Venkataraman P; DeSouza N; Sait SN; Driscoll DL; Gibbs JF
Clin Cancer Res; 2003 Oct; 9(13):4935-43. PubMed ID: 14581368
[TBL] [Abstract][Full Text] [Related]
26. [Prognostic value of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
Zhao E; Han D; Yu Z; Fan E; Li Y; Zhou Z
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2002 Nov; 16(11):599-602. PubMed ID: 15515548
[TBL] [Abstract][Full Text] [Related]
27. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of stromelysin-3 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer.
Sharma R; Chattopadhyay TK; Mathur M; Ralhan R
Oncology; 2004; 67(3-4):300-9. PubMed ID: 15557792
[TBL] [Abstract][Full Text] [Related]
29. Prognosis of gastric carcinoma revealed by interactions between tumor cells and basement membrane.
Grigioni WF; D'Errico A; Fortunato C; Fiorentino M; Mancini AM; Stetler-Stevenson WG; Sobel ME; Liotta LA; Onisto M; Garbisa S
Mod Pathol; 1994 Feb; 7(2):220-5. PubMed ID: 8008747
[TBL] [Abstract][Full Text] [Related]
30. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer.
Murray GI; Duncan ME; O'Neil P; McKay JA; Melvin WT; Fothergill JE
J Pathol; 1998 Jul; 185(3):256-61. PubMed ID: 9771478
[TBL] [Abstract][Full Text] [Related]
31. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
Wang L; Madigan MC; Chen H; Liu F; Patterson KI; Beretov J; O'Brien PM; Li Y
Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological Variation of Lauren Classification in Gastric Cancer.
Chen YC; Fang WL; Wang RF; Liu CA; Yang MH; Lo SS; Wu CW; Li AF; Shyr YM; Huang KH
Pathol Oncol Res; 2016 Jan; 22(1):197-202. PubMed ID: 26502923
[TBL] [Abstract][Full Text] [Related]
33. Matrix metalloproteinase-9 is associated with disease-free survival and overall survival in patients with gastric cancer.
Chu D; Zhang Z; Li Y; Zheng J; Dong G; Wang W; Ji G
Int J Cancer; 2011 Aug; 129(4):887-95. PubMed ID: 20957628
[TBL] [Abstract][Full Text] [Related]
34. Matrix metalloproteinase-14 is a negative prognostic marker for patients with gastric cancer.
He L; Chu D; Li X; Zheng J; Liu S; Li J; Zhao Q; Ji G
Dig Dis Sci; 2013 May; 58(5):1264-70. PubMed ID: 23314917
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical evaluation of type IV collagenase (72-kd metalloproteinase) in prostatic intraepithelial neoplasia.
Montironi R; Lucarini G; Castaldini C; Galluzzi CM; Biagini G; Fabris G
Anticancer Res; 1996; 16(4A):2057-62. PubMed ID: 8712742
[TBL] [Abstract][Full Text] [Related]
36. Expression of collagenase-3 (matrix metalloproteinase-13) in human gastric cancer.
Elnemr A; Yonemura Y; Bandou E; Kinoshita K; Kawamura T; Takahashi S; Tochiori S; Endou Y; Sasaki T
Gastric Cancer; 2003; 6(1):30-8. PubMed ID: 12673424
[TBL] [Abstract][Full Text] [Related]
37. Analysis of expression of matrix metalloproteinases-2 and -9 in hypopharyngeal squamous cell carcinoma by in situ hybridization.
Miyajima Y; Nakano R; Morimatsu M
Ann Otol Rhinol Laryngol; 1995 Sep; 104(9 Pt 1):678-84. PubMed ID: 7661515
[TBL] [Abstract][Full Text] [Related]
38. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma.
Herbst RS; Yano S; Kuniyasu H; Khuri FR; Bucana CD; Guo F; Liu D; Kemp B; Lee JJ; Hong WK; Fidler IJ
Clin Cancer Res; 2000 Mar; 6(3):790-7. PubMed ID: 10741698
[TBL] [Abstract][Full Text] [Related]
39. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
Beyer BC; Heiss MM; Simon EH; Gruetzner KU; Babic R; Jauch KW; Schildberg FW; Allgayer H
Cancer; 2006 Mar; 106(5):1026-35. PubMed ID: 16435385
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma.
Li HC; Cao DC; Liu Y; Hou YF; Wu J; Lu JS; Di GH; Liu G; Li FM; Ou ZL; Jie C; Shen ZZ; Shao ZM
Breast Cancer Res Treat; 2004 Nov; 88(1):75-85. PubMed ID: 15538048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
